{"url_path":"/sec/silo/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-056079-index.html","accession_number":"0001213900-26-056079","cik":"0001514183","ticker":"SILO","issuer_name":"Silo Pharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1514183/0001213900-26-056079-index.html","primary_entity_key":"0001514183","primary_entity_name":"Silo Pharma, Inc."},"word_count":435,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n \n\n☒ **QUARTERLY REPORT UNDER SECTION 13 OR\n15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For the quarterly period ended March 31, 2026**\n\n \n\nor\n\n \n\n☐ **TRANSITION REPORT UNDER SECTION 13 OR\n15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from ___________ to ___________\n\n \n\n**Commission File Number: 001-41512**\n\n \n\n**SILO PHARMA, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**   **27-3046338**\n\n(State or other jurisdiction of\n\nincorporation or organization)   (IRS Employer\n\nIdentification No.)\n\n \n\n**677 N. Washington Boulevard,**\n\n**Sarasota, Florida**\n  **34236**\n\n(Address of principal executive offices)   (Zip code)\n\n \n\nRegistrant’s telephone number, including\narea code: **(718) 400-9031**\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Exchange Act:\n\n \n\n**Title of each class**   **Trading Symbol(s)**   **Name of exchange on which registered**\n\nCommon Stock, par value $0.0001 per share   SILO   The Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant\n(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months\n(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements\nfor the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nhas submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405\nof this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit such files).\nYes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant\nis a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.\nSee the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”\nand “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer  ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒ Smaller reporting company ☒\n\n  Emerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant\nis a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nNumber of shares of common stock, par value $0.0001\nper share, outstanding as of May 13, 2026 was: 16,266,593.\n\n \n\n \n\n \n\n**SILO PHARMA, INC. AND SUBSIDIARY\nFORM 10-Q\nMARCH 31, 2026**\n\n** **\n\n**TABLE OF CONTENTS**\n\n \n\n \n \n**Page**\n\n[**PART I – FINANCIAL INFORMATION**](#a_001)"}